MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318151 | Name: Lidocaine Hydrochloride Monohydrate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lidocaine hydrochloride is a local anesthetic and cardiac depressant used as an antiarrhythmia agent. Originally developed as a local anesthetic, it has properties as a class IB antiarrhythmic, a long-acting membrane stabilizing agent used against ventricular arrhythmia. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacine or prilocaine.

Chemical Structure

Lidocaine Hydrochloride Monohydrate
Lidocaine Hydrochloride Monohydrate
CAS#6108-05-0 (HCl monohydrate)

Theoretical Analysis

MedKoo Cat#: 318151

Name: Lidocaine Hydrochloride Monohydrate

CAS#: 6108-05-0 (HCl monohydrate)

Chemical Formula: C14H25ClN2O2

Exact Mass:

Molecular Weight: 288.82

Elemental Analysis: C, 58.22; H, 8.73; Cl, 12.27; N, 9.70; O, 11.08

Price and Availability

Size Price Availability Quantity
5g USD 250.00 2 Weeks
25g USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
73-78-9 (HCl); 6108-05-0 (HCl monohydrate)
Synonym
Lidocaine Hydrochloride; LIDOCAINE HCL; Lidothesin; Lignocaine hydrochloride; Xyloneural; Xylocitin;
IUPAC/Chemical Name
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;hydrate;hydrochloride
InChi Key
IYBQHJMYDGVZRY-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H22N2O.ClH/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4;/h7-9H,5-6,10H2,1-4H3,(H,15,17);1H
SMILES Code
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Lidocaine (Lignocaine) hydrochloride hydrate inhibits sodium channels involving complex voltage and using dependence.
In vitro activity:
The MKN45 cell viability, proliferation, and apoptosis were determined after cells were treated by lidocaine. According to CCK-8 assay, cell viability was inhibited after cells were cultured with different concentrations of lidocaine (1, 5 and 10 mM) (Fig. 1a). Lidocaine inhibited migration (p < 0.05, Fig. 2a) and down-regulated MMP-2, and -9 expression (p < 0.05, Fig. 2b). Reference: BMC Cancer. 2019 Mar 15;19(1):233. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419442/
In vivo activity:
In this study, the potential role of lidocaine in DPN is explored, and the possible mechanisms are investigated. The rat DPN model is constructed through administration of streptozotocin (STZ, 60 mg/kg). The experimental results demonstrate that lidocaine remarkably downregulates the mRNA and protein expressions of the c-Jun signaling pathway in serum and DRGs induced with DPN. Reference: Contrast Media Mol Imaging. 2022 Aug 17;2022:1888153. https://pubmed.ncbi.nlm.nih.gov/36072636/

Preparing Stock Solutions

The following data is based on the product molecular weight 288.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Liu X, Zheng F, Tian L, Li T, Zhang Z, Ren Z, Chen X, Chen W, Li K, Sheng J. Lidocaine inhibits influenza a virus replication by up-regulating IFNα4 via TBK1-IRF7 and JNK-AP1 signaling pathways. Int Immunopharmacol. 2023 Jan 11;115:109706. doi: 10.1016/j.intimp.2023.109706. Epub ahead of print. PMID: 36638664. 2. Sui H, Lou A, Li Z, Yang J. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233. doi: 10.1186/s12885-019-5431-9. PMID: 30876463; PMCID: PMC6419442. 3. Luo J, Wu D, Wu Q, Chen Y, Gan Y, He M, Sun W, Ai Y, Su Q, Zou X, Wang D. Lidocaine Ameliorates Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats through Modulating the c-Jun Signaling Pathway. Contrast Media Mol Imaging. 2022 Aug 17;2022:1888153. doi: 10.1155/2022/1888153. PMID: 36072636; PMCID: PMC9402326. 4. Chen YC, Chang HN, Pang JS, Lin LP, Chen JM, Yu TY, Tsai WC. Lidocaine Inhibited Tendon Cell Proliferation and Extracellular Matrix Production by Down Regulation of Cyclin A, CDK2, Type I and Type III Collagen Expression. Int J Mol Sci. 2022 Aug 7;23(15):8787. doi: 10.3390/ijms23158787. PMID: 35955918; PMCID: PMC9368801.
In vitro protocol:
1. Liu X, Zheng F, Tian L, Li T, Zhang Z, Ren Z, Chen X, Chen W, Li K, Sheng J. Lidocaine inhibits influenza a virus replication by up-regulating IFNα4 via TBK1-IRF7 and JNK-AP1 signaling pathways. Int Immunopharmacol. 2023 Jan 11;115:109706. doi: 10.1016/j.intimp.2023.109706. Epub ahead of print. PMID: 36638664. 2. Sui H, Lou A, Li Z, Yang J. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233. doi: 10.1186/s12885-019-5431-9. PMID: 30876463; PMCID: PMC6419442.
In vivo protocol:
1. Luo J, Wu D, Wu Q, Chen Y, Gan Y, He M, Sun W, Ai Y, Su Q, Zou X, Wang D. Lidocaine Ameliorates Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats through Modulating the c-Jun Signaling Pathway. Contrast Media Mol Imaging. 2022 Aug 17;2022:1888153. doi: 10.1155/2022/1888153. PMID: 36072636; PMCID: PMC9402326. 2. Chen YC, Chang HN, Pang JS, Lin LP, Chen JM, Yu TY, Tsai WC. Lidocaine Inhibited Tendon Cell Proliferation and Extracellular Matrix Production by Down Regulation of Cyclin A, CDK2, Type I and Type III Collagen Expression. Int J Mol Sci. 2022 Aug 7;23(15):8787. doi: 10.3390/ijms23158787. PMID: 35955918; PMCID: PMC9368801.
1: Wen X, Xu S, Zhang Q, Li X, Liang H, Yang C, Wang H, Liu H. Inhibitory gene expression of the Cav3.1 T-type calcium channel to improve neuronal injury induced by lidocaine hydrochloride. Eur J Pharmacol. 2016 Mar 15;775:43-9. doi: 10.1016/j.ejphar.2016.02.019. Epub 2016 Feb 4. PubMed PMID: 26852957. 2: Arbelaez-Camargo D, Suñé-Negre JM, Roig-Carreras M, García-Montoya E, Pérez-Lozano P, Miñarro-Carmona M, Ticó-Grau JR. Preformulation and characterization of a lidocaine hydrochloride and dexamethasone sodium phosphate thermo-reversible and bioadhesive long-acting gel for intraperitoneal administration. Int J Pharm. 2016 Feb 10;498(1-2):142-52. doi: 10.1016/j.ijpharm.2015.12.012. Epub 2015 Dec 10. PubMed PMID: 26685726. 3: Badawi HM, Förner W, Ali SA. The molecular structure and vibrational, (1)H and (13)C NMR spectra of lidocaine hydrochloride monohydrate. Spectrochim Acta A Mol Biomol Spectrosc. 2016 Jan 5;152:92-100. doi: 10.1016/j.saa.2015.07.060. Epub 2015 Jul 10. PubMed PMID: 26196935. 4: Zhang J, Zhu J, Yao X, Duan Y, Zhou X, Yang M, Li X. Pharmacokinetics of Lidocaine Hydrochloride Metabolized by CYP3A4 in Chinese Han Volunteers Living at Low Altitude and in Native Han and Tibetan Chinese Volunteers Living at High Altitude. Pharmacology. 2016;97(3-4):107-13. doi: 10.1159/000443332. Epub 2016 Jan 6. PubMed PMID: 26730802. 5: Bebawy LI, Elghobashy MR, Abbas SS, Shokry RF. Chromatographic Determination of Aminoacridine Hydrochloride, Lidocaine Hydrochloride and Lidocaine Toxic Impurity in Oral Gel. J Chromatogr Sci. 2015 Dec 15. pii: bmv170. [Epub ahead of print] PubMed PMID: 26671412. 6: Liu B, Ding L, Xu X, Lin H, Sun C, You L. Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration. Eur J Drug Metab Pharmacokinet. 2015 Dec;40(4):409-15. doi: 10.1007/s13318-014-0218-5. Epub 2014 Jul 17. PubMed PMID: 25031074. 7: Aleman M, Davis E, Williams DC, Madigan JE, Smith F, Guedes A. Electrophysiologic Study of a Method of Euthanasia Using Intrathecal Lidocaine Hydrochloride Administered during Intravenous Anesthesia in Horses. J Vet Intern Med. 2015 Nov-Dec;29(6):1676-82. doi: 10.1111/jvim.13607. Epub 2015 Aug 30. PubMed PMID: 26332487. 8: Wang Y, Zhang L, Li C, Wang H, Li Q. [Preliminary study on transdermal characteristics and sunface anesthetic effects of lidocaine hydrochloride loaded trans-activator of transcription peptide conjugated nano-niosome in animals]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2015 Jul;50(7):423-7. Chinese. PubMed PMID: 26564747. 9: Lalfamkima F, Debnath SC, Adhyapok AK. A study of promethazine hydrochloride and pentazocine intramuscular sedation along with 2 % lidocaine hydrochloride and adrenaline and comparison to placebo along with 2 % lidocaine hydrochloride and adrenaline for surgical extraction of mandibular third molar. J Maxillofac Oral Surg. 2015 Mar;14(1):90-100. doi: 10.1007/s12663-013-0595-3. Epub 2013 Nov 30. PubMed PMID: 25729232; PubMed Central PMCID: PMC4339336. 10: Sun N, Zhu Y, Yuan L, Lang B. Nano-liposomes of entrapment lidocaine hydrochloride on in vitro permeability of narcotic. Pak J Pharm Sci. 2015 Jan;28(1 Suppl):325-8. PubMed PMID: 25631510. 11: Hirata K, Mohammed D, Hadgraft J, Lane ME. Influence of lidocaine hydrochloride and penetration enhancers on the barrier function of human skin. Int J Pharm. 2014 Dec 30;477(1-2):416-20. doi: 10.1016/j.ijpharm.2014.10.012. Epub 2014 Oct 8. PubMed PMID: 25305378. 12: Dariolli R, Takimura CK, Campos CA, Lemos PA, Krieger JE. Development of a closed-artery catheter-based myocardial infarction in pigs using sponge and lidocaine hydrochloride infusion to prevent irreversible ventricular fibrillation. Physiol Rep. 2014 Aug 28;2(8). pii: e12121. doi: 10.14814/phy2.12121. Print 2014 Aug 1. PubMed PMID: 25168871; PubMed Central PMCID: PMC4246577. 13: Vidhya N, Karthikeyan BS, Velmurugan N, Abarajithan M, Nithyanandan S. Interaction between lidocaine hydrochloride (with and without adrenaline) and various irrigants: A nuclear magnetic resonance analysis. Dent Res J (Isfahan). 2014 May;11(3):395-9. PubMed PMID: 25097652; PubMed Central PMCID: PMC4119375. 14: Preis M, Woertz C, Schneider K, Kukawka J, Broscheit J, Roewer N, Breitkreutz J. Design and evaluation of bilayered buccal film preparations for local administration of lidocaine hydrochloride. Eur J Pharm Biopharm. 2014 Apr;86(3):552-61. doi: 10.1016/j.ejpb.2013.12.019. Epub 2014 Jan 1. PubMed PMID: 24388912. 15: Moch C, Salmon D, Rodríguez Armesto L, Colombel M, Pivot C, Pirot F. Bladder tissue permeability and transport modelling of intravesical alum, lidocaine hydrochloride, methylprednisolone hemisuccinate and mitomycin C. Int J Pharm. 2014 Apr 10;464(1-2):91-103. doi: 10.1016/j.ijpharm.2014.01.021. Epub 2014 Jan 22. PubMed PMID: 24463072. 16: Bhatia G, Banga AK. Effect of modulated alternating and direct current iontophoresis on transdermal delivery of lidocaine hydrochloride. Biomed Res Int. 2014;2014:537941. doi: 10.1155/2014/537941. Epub 2014 May 15. PubMed PMID: 24959580; PubMed Central PMCID: PMC4052077. 17: Dogrul A, Arslan SA, Tirnaksiz F. Water/oil type microemulsion systems containing lidocaine hydrochloride: in vitro and in vivo evaluation. J Microencapsul. 2014;31(5):448-60. doi: 10.3109/02652048.2013.879926. Epub 2014 Apr 3. PubMed PMID: 24697177. 18: Fabi SG, Champagne JP, Nettar KD, Maas CS, Goldman MP. Efficacy and safety of and patient satisfaction with injectable hyaluronic acid with 0.3% lidocaine hydrochloride for the treatment of superficial perioral lines or superficial lateral canthal lines. Dermatol Surg. 2013 Nov;39(11):1613-20. doi: 10.1111/dsu.12336. Epub 2013 Oct 9. PubMed PMID: 24118510. 19: Jog M, Sachidananda R, Saeed K. Risk of contamination of lidocaine hydrochloride and phenylephrine hydrochloride topical solution: in vivo and in vitro analyses. J Laryngol Otol. 2013 Aug;127(8):799-801. doi: 10.1017/S0022215113001564. Epub 2013 Jul 30. PubMed PMID: 23899822. 20: Shimada Y, Goto S, Uchiro H, Hirota K, Terada H. Characteristics of amorphous complex formed between indomethacin and lidocaine hydrochloride. Colloids Surf B Biointerfaces. 2013 May 1;105:98-105. doi: 10.1016/j.colsurfb.2012.12.026. Epub 2012 Dec 31. PubMed PMID: 23352941.